Merck’s RSV drug meets key end-stage trial targets

Merck said Tuesday that its respiratory syncytial virus (RSV) drug met safety and efficacy targets in a mid- to late-stage study testing it in infants.

Compartir esta publicacion:

ENTRADAS POPULARES
SÍGANOS
Danos like en facebook
Síganos en Twitter
Suscríbase a nuestro canal
Tik Tok
TRANSMISIÓN EN VIVO